1. Morgan ML, Law N, Espino Barros Palau A, Saeed U, Yalmanchili S, Lee AG. Anti-asialo-GM1 and GD1a variant of Miller Fisher variant of Guillain-Barré Syndrome. J Neuroophthalmol. 2014; 34:377–379.
Article
2. Fusco C, Bertani G, Scarano A, Giustina ED. Acute ophthalmoparesis associated with anti-GM1, anti-GD1a, and anti-GD1b antibodies after enterovirus infection in a 6-year-old girl. J Child Neurol. 2007; 22:432–434.
Article
3. Kim JK, Bae JS, Kim DS, Kusunoki S, Kim JE, Kim JS, et al. Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barré syndrome in Korea: a nationwide multicenter study. J Clin Neurol. 2014; 10:94–100.
Article
4. Simon O, Lacour A, Delval A, Beaume A, Vermersch P. Recurrent multiple cranial nerve palsy and anti-GD1a antibodies. Muscle Nerve. 2011; 43:447–448.
Article
5. Fujii D, Manabe Y, Takahasi Y, Narai H, Omori N, Kusunoki S, et al. A case of fisher-bickerstaff syndrome overlapped by guillain-barré syndrome. Case Rep Neurol. 2012; 4:212–215.
Article
6. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002; 125:2591–2625.
Article
7. Hamark C, Berntsson RP, Masuyer G, Henriksson LM, Gustafsson R, Stenmark P, et al. Glycans confer specificity to the recognition of ganglioside receptors by botulinum neurotoxin A. J Am Chem Soc. 2017; 139:218–230.
Article